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Background and purpose   Gaucher disease is heterogeneous. One 
of the most devastating complications is bone involvement, rang-
ing from mild osteopenia to osteonecrosis, but no markers have 
been discovered to predict onset and/or progression. We describe 
our experience in a large referral center using drilling for juxta-
articular osteonecrosis in young patients with Gaucher disease.
Patients and methods   We retrospectively reviewed medical 
data from all patients who were recommended to undergo drill-
ing for osteonecrosis of juxta-articular bone of the femoral head, 
the humeral head, or upper tibia for acute osteonecrosis at a pre-
collapse stage.
Results   11 patients (mean age 34 years) underwent drilling of 
12 joints with juxta-articular osteonecrosis; 3 (mean age 51 years) 
refused intervention. 9 joints that were drilled showed advancing 
joint degeneration within 0.5 to 4 years. 3 joints have undergone 
replacement. Of the 3 joints that did not undergo drilling, 2 have 
undergone replacement and 1 has collapsed with osteoarthritis.
Interpretation      We  found  equally  poor  outcome  with  and 
without drilling. Effective intervention can only be achieved by 
improving our understanding of bone physiology and pathophysi-
ology in Gaucher disease.  

Gaucher disease is the most common lysosomal storage dis-
ease, and occurs in approximately 1 in 50,000 live births. It is 
more common in Ashkenazi Jews where it occurs in approx-
imately 1 in 850 live births (Beutler and Grabowski 2001). 
There is accumulation of lipids due to deficient β-glucocer-
ebrosidase, but neither enzyme activity nor other genetic or 
biochemical biomarkers can predict onset or severity of dis-
ease progression (Beutler and Grabowski 2001). One of the 
most devastating consequences of the disease is bone involve-
ment, which affects most patients (Elstein et al. 1997). The 
underlying pathology of bone in Gaucher disease is unclear, 
but it is postulated to be secondary to bone marrow infiltration 
by lipid-laden macrophages, causing vascular occlusion or a 
local inflammatory reaction (Cox 2001). There are recognized 
risk factors for bone disease in Gaucher disease (Rodrigue et 
al. 1999) such as splenectomy (especially in childhood) and 
the presence of alleles that produce little or no enzyme. Bone 
involvement  ranges  in  severity  from  discrete  radiographic 
findings such as the Erlenmeyer flask deformity of the distal 
femur and the “herringbone” pattern of the humerus diaphy-
sis, to osteopenia and osteonecrosis (Itzchaki et al. 2004).
Enzyme replacement therapy (ERT) (Genzyme Corp., Cam-
bridge, MA) improves the visceral and hematological features 
of the disease (Barton et al. 1991) as well as sense of well-
being (Giraldo et al. 2005). Even so, the effect of ERT on bone 
remains controversial since there is not necessarily a correla-
tion between radiological improvement (Poll et al. 2002) and 
clinical lack of deterioration (Elstein et al. 1996). ERT may 
eliminate bone crises if treatment is begun early (Charrow et 
al. 2007), but ERT does not appear to reverse existing osteo-
necrosis. To date, there are no definitive theories to explain the 
inadequate response of affected bone to ERT. 
Invasive interventions have been recommended for the pre-
collapse stages of femoral osteonecrosis in otherwise healthy 
patients (Mont et al. 2006), to prolong time to replacement 
(McGory et al. 2007). Core decompression was used by Ficat 
(1983) with good results (79% success rate in patients with 
disease of stages I–II). When used in sickle cell anemia and 
compared to physical therapy, however, no additional benefit 
was noted (Neumayr et al. 2006). Yet, it is possible that the 
bone marrow may be impacted directly by decompression in 
sickle cell disease if attempted early in the progression to col-
lapse (Hernigou et al. 2006).
The cause of osteonecrosis in Gaucher disease may be in 
the marrow; thus, drilling of affected bones in Gaucher dis-
ease seems tenable. We report our experience using drilling 
for joint osteonecrosis in patients with Gaucher disease.202  Acta Orthopaedica 2009; 80 (2): 201–204
Patients and methods 
We  retrospectively  reviewed  all  patients  recommended  to 
undergo  small-diameter  drilling  for  osteonecrosis  of  juxta-
articular bone of the femoral head, the humeral head, or upper 
tibia for acute osteonecrosis in a pre-collapse stage, ARCO 
stages  1–2  (Gardeniers  1993).  Excluded  from  the  current 
report  were  patients  sustaining  nonarticular  osteonecrosis 
(which is not uncommon in Gaucher disease), and those in 
whom late results of osteonecrosis were diagnosed (collapse 
was already evident in the hip, knee, or shoulder). 
Of 618 patients diagnosed as having Gaucher disease (by 
enzymatic testing and genetic analysis), 11 patients had drill-
ing of 12 joints. 3 additional patients refused intervention. 
None of these patients were lost to follow-up.
Diagnosis of osteonecrosis was based on acute joint pain 
and verified by MR imaging. Sphericity of the joint head was 
assessed by radiographs and CT. Staging of the lesion was 
based on the ARCO system for femoral osteonecrosis with 
modifications for other bones, but using the same evaluators 
as for the hip. 
The size of lesions is not stated in this report since radiologi-
cal findings within the bone marrow are evident in all cases but 
delineation of borders of osteonecrosis and Gaucher-related 
lesions are difficult to define. Invariably (and universally), the 
medullary lesions in Gaucher bone are accompanied by abnor-
mal matrix composition (Figure 1) that often raise conflicting 
radiological signals and complicate the reading of acute or 
chronic involvement. The presence of artifacts on MRI further 
confuses attempts at delineation of the borders of the affected 
area. 
11 patients underwent drilling (Table 1) and 3 did not accept 
drilling (Table 2). The patients were followed for 2–16 years. 
Drilling  was  done  percutaneously  with  a  5-mm  drill  bit 
under  general  or  spinal  anesthesia  and  using  fluoroscopic 
guidance. After cortical perforation, the drill was advanced 
into the osteonecrosis (according to MRI or radiographic find-
ings) while 4–6 medullary tracts were drilled into the necrotic 
region. In 3 patients (numbers 1–3), autologous bone marrow 
was aspirated from the ipsilateral iliac crest and injected into 
the drilled lesion. The lateral cortex perforation was left open 
in all cases. In 1 patient (number 8), contrast medium was 
injected into the drilled tunnel to improve visualization. Drains 
were not used. Postoperatively, all patients were encouraged 
to resume full range of joint motion and were advised to use 
crutches to prevent weight bearing on the treated limb (in the 
femur and tibia cases) for 6 weeks. Perioperative antibiotic 
was used for no more than 24 h. No complications occurred. 
Table 1. Demographic data of all patients who have undergone drilling
Patient   Sex  Age  Splen-  Genotype    Enzyme   Affected bone  ARCO 
    at    ectomy      replacement    stage at
       event      therapy at     diagnosis a
          event
  1    M   26   No   1226/1226   Yes   Femoral head   1
  2    M   21   No   1226/84GG   No   Femoral head   2
  3    F   33  No   1226/84GG   Yes   Proximal tibia   2
  4    M   47   Yes   1226/1226   No   Femoral head   2
  5    F   32   No   1226/1448   Yes   Humeral head   1
  6    M   41   No   1226/1226   No   Humeral heads  2, 2
  7   M   42   Yes   1226/IVS  No   Femoral head   2
  8    M   36   No   1226/?   No   Femoral head   1
  9    M   15   Yes   1226/84GG   No   Femoral head   1
  10    M   26   No   1226/1226   No   Femoral head   1
  11   M   31   No   1226/1226   No   Femoral head   1
a for explanation of ARCO staging, see text.
Figure 1. Typical view of Gaucher bony milieu (taken 
during drilling).
Table 2. Demographic data of patients who did not agree to intervention 
Patient   Sex  Age  Splen-  Genotype    Enzyme   Affected bone  ARCO  Evolution 
        ectomy      replacement    stage at  (time/status)
             therapy      diagnosis 
  1    F   33   No   1226/1226   Yes   Femoral head  1  1 year / hip replacement
  2    M   51   No   1226/84GG   Yes   Femoral head  1   1 year / hipreplacement
  3    M   69   No   1226/1226   Yes    Proximal tibia  1   3 years / stage 3 (osteoarthritis of knee a)
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Results (Table 3)
2 of the 11 drilled patients did not develop articular collapse 
and joint derangement; these patients are currently free of pain 
and have functional joint motion (1 shoulder with 16 years 
of follow-up and 1 hip with 4 years of follow-up). These 2 
patients (numbers 5 and 10, respectively) had osteonecrotic 
lesions farther from the joint surface than the others (Figure 
2).
 All other patients (9 joints) showed advancing joint degen-
eration within 0.5–4 years. Of these 8 patients, 5 underwent 
hip joint replacement by prosthetic implant. 1 patient (number 
2) underwent hip-adductor tenotomy to improve hip range of 
motion and currently shows joint ankylosis but is unwilling 
to consider any further intervention. The remaining patients 
(numbers 1 and 6) are currently not in need of surgical inter-
vention but have evidence of a degenerative joint. 
All 3 patients who elected for no intervention progressed to 
articular surface collapse. The 2 patients with femoral head 
involvement underwent total hip replacement within 2 years 
of osteonecrosis. The patient with tibial plateau depression 
uses a knee brace and ambulates freely.
Discussion
Osteonecrosis of the femoral head, the humeral head, or the 
tibial knee surface is a devastating consequence of Gaucher 
disease. Core decompression or drilling can change the course 
of  osteonecrosis  in  its  early  stages  in  populations  without 
Gaucher Disease (Steinberg et al. 2001), but this type of inter-
vention for early stages of osteonecrosis in Gaucher disease 
has never been studied.
For the current cohort, drilling was recommended immedi-
ately, i.e. when articular cartilage damage was not yet evident 
(ARCO stages 0–2). Thus, intervention should have prevented 
subchondral collapse and subsequent degeneration of the joint. 
Surprisingly, local complications such as fracture, infection, 
or substantial bleeding were not encountered, negating a long-
standing belief that patients with Gaucher disease are prone to 
infection and bleeding. However, this highlights the poor out-
come of intervention itself in the current cohort: only 2 of 12 
joints have not progressed to osteoarthritis. Moreover, these 2 
were the only joints where the lesions were quite distant from 
the joint, and possibly for this reason there was no collapse. 
Drilling of necrotic bone is believed to accelerate osteo-
clast recruitment, substitution of dead bone, release of large 
amounts of bone morphogenic proteins and other factors from 
bone,  platelets,  endothelium,  and  monocytes  (Seyler  et  al. 
2007), thus accelerating bone healing. Our findings of lack 
of efficacy of intervention by drilling raise two hypothetical 
explanations.  Either  the  process  as  diagnosed  by  imaging 
techniques is different from what we diagnose as osteonecro-
sis of other etiologies (Mont et al. 2007) or some factor(s) in 
the medullary milieu in Gaucher disease prevent(s) healing. 
Elevated serum levels of cytokines of the TNF superfam-
ily have been noted in Gaucher disease (Allen et al. 1997, 
Barack et al. 1999). Such high levels might negate the osteo-
Figure 2. Chronological sequence in patient 10, who did not develop articular collapse and joint derangement. At 
presentation (A), at 1.5 years (B), and at 2 years (C).
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Table 3. Outcome in patients undergoing drilling 
Patient  Affected bone  ARCO   Time from  Years to  
    stage at   diagnosis  ARCO
    drilling  and drilling  stage 4
  1    Femoral head   1     1 week   1.5
  2    Femoral head  2   10 months   2
  3   Proximal tibia   2     4 months   2
  4    Femoral head   2     3 months   2
  5    Humeral head   1   14 months   No progression 
  6    Humeral heads   2, 2     8 months    4, 4
  7    Femoral head   2     1 month   1
  8    Femoral head   1   11 months   1
  9    Femoral head   1   18 months    3
  10    Femoral head   1     2 months   No progression
  11   Femoral head   1     2 weeks   0.5204  Acta Orthopaedica 2009; 80 (2): 201–204
blast induction effect of bone drilling. Gaucher cells (lipid-
engorged macrophages) might also have toxic effects in this 
milieu (although fracture healing is normal in patients with 
Gaucher disease). Bone collapse was evident even in a non-
weight bearing bone such as the head of humerus, demonstrat-
ing that limiting ambulation will not necessarily prevent col-
lapse. 
Drilling of necrotic bone might actually accelerate osteo-
clastic activity in a non-favorable marrow homeostasis. The 
osteoclast-osteoblast balance of bone resorption coupled with 
new bone formation may not be preserved in Gaucher disease 
(leading to osteopenia and a high prevalence of trabecular bone 
fractures). Thus, adding osteoclast inhibitors such as bisphos-
phonates might help to prevent aggressive bone resorption 
without laying new trabecular bone that will support subchon-
dral bone. Only 1 patient (number 1) was already receiving 
alendronate because of inclusion in a clinical trial (Wenstrup 
et al. 2004) before osteonecrosis occurred, and yet collapse 
occurred at least as quickly as in the other cases. 
We can only hypothesize that our findings are more com-
parable to those seen in sickle cell anemia than in other bone 
pathologies, which indicate a lack of responsiveness by the 
marrow to clear the dead bone and/or to induce new trabecular 
bone formation under conditions of Gaucher-induced osteo-
necrosis. Whether this also indicates that the bony necrosis 
in Gaucher disease is inherently unique—or that a secondary 
(epigenetic) set of factors such as those induced by inflam-
mation and inflammatory cytokines is detrimental to bone—
cannot be determined from our clinical observations. 
EL and MI did all the surgical procedures; EL and MP gathered the data; DE 
and EL devised the study; DE wrote the manuscript; and AZ is the Director of 
the Gaucher Clinic and oversees all the patients.
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